Kornimate/medical-research-clean huggingface dataset:
factors contributing to cardiovascular morbidity and mortality in patients with gastrointestinal bleeding

Conditions: Gastrointestinal Bleeding; Acute Coronary Syndrome

Summary: the rate of complication and death of patients with acute digestive tract bleeding is increased in the setting of acute coronary heart disease. the aim of the study is to establish the relative importance of the risk factors contributing to the death rate from acute digestive tract bleeding in patients admitted with acute coronary heart disease.

the rate of complication and death of patients with acute digestive tract bleeding is increased in the setting of acute coronary heart disease. the aim of the study is to establish the relative importance of the risk factors contributing to the death rate from acute digestive tract bleeding in patients admitted with acute coronary heart disease. this study will be conducted at mmc and involve collecting your clinical information from our medical records and computer systems. approximately 200 adult patients with acute coronary heart disease and acute digestive tract bleeding admitted to mmc will be enrolled and followed up for 1 year after recruitment. we propose to develop criteria and a scoring system that will assist your doctors in caring for patients like you in the future.

Eligibility criteria:
inclusion criteria: * consecutive patients with acute cs and acute gi bleeding

Keywords: acute gastrointestinal bleeding acute coronary syndrome
safety study of grnopc1 in spinal cord injury

Conditions: Spinal Cord Injury

Summary: the purpose of the study is to evaluate the safety of grnopc1 administered at a single time-point between 7 and 14 days post injury, inclusive, to patients with neurologically complete spinal cord injuries (sci).


Eligibility criteria:
major inclusion criteria: * neurologically complete, traumatic sci (asia impairment scale a), zone of partial preservation \< 5 levels * last fully preserved neurological level from t-3 through t-11 * from 18 through 65 years of age at time of injury * single spinal cord lesion * informed consent for this protocol and the companion long term follow-up protocol must be provided and documented (i.e., signed informed consent forms) no later than 11 days following injury * able to participate in an elective surgical procedure to inject grnopc1 7-14 days following sci major exclusion criteria: * sci due to penetrating trauma * traumatic anatomical transection or laceration of the spinal cord * any concomitant injury or pre-existing condition that interferes with the performance, interpretation or validity of neurological examinations * inability to communicate effectively with neurological examiner * significant organ damage or systemic disease that would create an unacceptable risk for surgery or immunosuppression * history of any malignancy * pregnant or nursing women * body mass index (bmi) \> 35 or weight \> 300 lbs. * active participation in another experimental procedure/intervention

Keywords: spinal cord injury grnopc1
ocular safety of patients receiving macugen for neovascular age related macular degeneration

Conditions: Macular Degeneration

Summary: the study will provide additional safety data for specific safety events in persons receiving intravitreal injections. the committee for medicinal products for human use (chmp) is interested in obtaining additional safety information when macugen is used in real world settings by practitioners in europe treating patients with neovascular (wet) age-related macular degeneration (amd). the study will provide information about physician practice patterns and characteristics of patients treated with macugen.

no comparator patients with age-related macular degeneration

Eligibility criteria:
inclusion criteria: * neovascular amd patients who are eligible for macugen therapy based on the approved label exclusion criteria: * active or suspected ocular or periocular infection. known hypersensitivity to the active substance or any of its excipients.

Keywords: macular degeneration safety non-interventional non-randomized
a study comparing risankizumab to placebo in participants with active psoriatic arthritis (psa) who have a history of inadequate response to or intolerance to at least one disease modifying anti-rheumatic drug (dmard) therapy

Conditions: Psoriatic Arthritis

Summary: the purpose of this study is to compare the safety and efficacy of risankizumab versus placebo in participants with moderately to severely active psoriatic arthritis (psa).

the study consists of a screening period (approximately 35 days), period 1, period 2, and a 20-week follow-up period. period 1 is a 24-week randomized, double-blind, placebo-controlled, parallel-group treatment period. period 2 is the long-term treatment period and starts at week 24. to maintain the blind to the original treatment allocation, treatment at the week 24 visit is blinded: participants randomized to placebo receive blinded risankizumab 150 mg, and participants randomized to risankizumab receive blinded placebo. at week 28 and for the remaining dosing visits (to week 316), all participants are to receive open-label risankizumab 150 mg every 12 weeks. participants will remain blinded to the original randomization allocation for the duration of the study. the total study duration is 336 weeks including a telephone call 140 days (20 weeks) after last dose of study drug.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of psa with symptom onset at least 6 months prior to the screening visit and fulfillment of the classification criteria for psa (caspar) at the screening visit. * participant has active disease at baseline defined as ≥ 5 tender joints (based on 68 joint counts) and ≥ 5 swollen joints (based on 66 joint counts) * diagnosis of active plaque psoriasis with at least one psoriatic plaque of ≥ 2 cm diameter or nail changes consistent with psoriasis at screening visit. * participant has demonstrated an inadequate response or intolerance to or contraindication for conventional synthetic disease modifying anti-rheumatic drugs (csdmard) therapy(ies). * presence of either at screening: * ≥ 1 erosion on radiograph as determined by central imaging review or; * high sensitivity c-reactive protein (hscrp) ≥ 3.0 mg/l. exclusion criteria: * participant is considered by investigator, for any reason, to be an unsuitable candidate for the study. * participant has a known hypersensitivity to risankizumab. * participant has previous treatment with biologic agent.
study of peripheral blood non-coding rnas as diagnosis and prognosis biomarker for acute pancreatitis

Conditions: Acute Pancreatitis

Summary: it is important to identify patients with acute pancreatitis who are at risk for developing persistent organ failure early in the course of disease. the investigators evaluated whether peripheral blood non-coding rnas, including micrornas and long noncoding rna (lncrna), could serve as a good marker for detection of acute pancreatitis with persistent organ failure at early phase.

acute pancreatitis is a sudden inflammation of the pancreas. it can have severe complications and high mortality despite treatment. while mild cases are often successfully treated with conservative measures, such as fasting and aggressive intravenous fluid rehydration, severe cases may require admission to the intensive care unit or even surgery to deal with complications of the disease process. the diagnosis of severe acute pancreatitis at an early phase remain a major challenge for clinicians. therefore, many biologic markers have been studied in an effort to improve the diagnostic rate and determine the severity of acute pancreatitis but with disappointing results. non-coding rnas, including micrornas and long noncoding rna (lncrna), have recently been validated to stably exist in peripheral blood. several publications showed that it may serve as potential markers for various diseases, including cancer and inflammation. our current study evaluated whether and which kind of non-coding rnas could serve as good markers for severe acute pancreatitis.

Eligibility criteria:
inclusion criteria: * patients who was diagnosed acute pancreatitis * male or female * 18 years and older * written informed consent exclusion criteria: * symptoms of acute pancreatitis present for more than 72 hours * age under 18 years * pregnancy * patients unable to consent

Keywords: acute pancreatitis non-coding rna biological markers receiver operating characteristic curve post-ercp pancreatitis
three anticoagulation strategies for hemodialysis in patients at risk of hemorrhage

Conditions: Hemodialysis; Anticoagulation

Summary: the aim of our study is to assess three anticoagulation strategies for intermittent hemodialysis(ihd) in patients at risk of hemorrhage. a registry of consecutive hemodialysis patients with high risk of hemorrhage was conducted at the guangdong general hospital, the first affiliated hospital of guangzhou university of chinese medicine, the second affiliated hospital of guangzhou medicine university or guangzhou hospital of chinese medicine, between sep 10, 2017 and june 30th,2018. in this multi-center prospective and randomized study, participants were randomly divided into three groups during ihd according to different anticoagulation, including with regular saline flushes, one stage regional citrate anticoagulation (rca) and two-stage rca.

briefly, there are two parts in this study. the first part of the study is to compare two-stage rca with one stage rca during ihd, and the second part is to compare two-stage rca with regular saline flushes, with estimated total procedures, 78 and 48, respectively. the primary outcome was measured as therapy interruption based on visible serious circuit clotting or persistent alarms such as venous pressure (\> 200 mmhg) or tmp(transmembrane pressures) (\> 300 mmhg). the secondary outcomes included circuit survival time, the total clotting score of ecc(extracorporeal circuit ) and urea clearance (kt/v and urr). the total clotting score was the sum of the clotting scores for the venous expansion chamber, arterial expansion chamber, and dialyzer.

Eligibility criteria:
inclusion criteria: * age\>=18 years * intermittent hemodialysis patients that carry on a 4 hours hemodialysis procedure, 2-3 times one week. * the therapy mode is hemodialysis，with a dialysis fluid more than 500ml/min and blood flow volume more than 3.5-4ml/min.kg； * at risk of hemorrhage,including active hemorrhage(within 3 days),post-operation(within 3 days) and pre-invasive operation(within 7 days). exclusion criteria: * at high risk of citrate accumulation( total bilirubin \>60umol/l; lactic acid\>3mmol/l,）； * use the drugs that impact the coagulation function within 7 days; * serious hypocalcemia (serum calcium\<1.9mmol/l).
effects of gw679769 on sleep onset and maintenance and next day functioning in subjects with primary insomnia

Conditions: Sleep Initiation and Maintenance Disorders; Insomnia

Summary: this study is designed to find the optimal (best) doses of gw679769 that could be given daily to promote sleep onset and maintain sleep during the night without significant next-day thinking impairment and drowsiness in subjects with primary insomnia.


Eligibility criteria:
inclusion criteria: * difficulty going to sleep and/or staying asleep for at least the past 3 months. * insomnia must result in significant distress or impairment in functioning at home, socially or at work. * otherwise good health with no significant or unstable medical disorder including psychiatric, neurological, endocrine, heart, lung or gastrointestinal disorders, drug/alcohol abuse, cognitive impairment, cancer or chronic pain conditions such as arthritis. exclusion criteria: * history of other sleep disorders such as sleep apnea or restless leg syndrome. * regular sleep habits, including bedtime between 9 pm and midnight. * no nightshift/rotating shift work, frequent napping or planned travel across \>2 time zones. * use of nicotine, caffeine and alcoholic products.

Keywords: cognition polysomnography primary insomnia electroencephalography sleep
association between mitochondrial dna content and risk of coronary heart disease

Conditions: Coronary Heart Disease

Summary: compelling epidemiological evidence indicates that alterations of mitochondrial dna, including mutations and abnormal content of mitochondrial dna (mtdna), are associated with the initiation and development of cardiovascular disease. this study was undertaken to investigate whether mtdna copy number in peripheral blood cells could be used as a risk predictor for coronary heart disease.


Eligibility criteria:
inclusion criteria: 1. history of documented myocardial infarction; 2. prior coronary revascularization intervention (coronary artery bypass graft surgery or percutaneous coronary intervention); 3. the presence of ≥ 50% stenosis in one or more coronary arteries identified during cardiac catheterization; exclusion criteria: 1. history of malignancy or end-stage renal disease; 2. blood transfusion within one month or prior bone marrow transplantation 3. patients who reluctant to sign informed consent

Keywords: mitochondrial dna copy number peripheral blood cells
exploring unconventional plant-derived metabolites for glycemic control: the case of pomegranate

Conditions: Prediabetes

Summary: the explorer study will investigate whether supplementation with a pomegranate extract rich in ellagitannins is able to improve well-being and metabolic health in individuals without diabetes. the aim is to establish for the first time an association between the intake of ellagitanninsa and glycaemic control, the processing/aggregation of iapp (a protein associated with diabetes), the state of the intestinal microbiota and circulating levels of urolithin b (a small bioavailable molecule resulting from the metabolism of ellagitannins). this is a 12-week pilot study that is double-blind (neither participants nor researchers know who gets the treatment) and placebo-controlled (some people will receive a non-active substance). it will involve volunteers who do not have diabetes. phase 1 - recruitment: volunteers without diabetes, who are patients at a family health unit, will be recruited. participants will provide informed consent and information such as sociodemographic and biochemical data. phase 2 - intervention: the recruited individuals will be divided into two groups: one receiving the pomegranate extract supplement (intervention group) and the other receiving a placebo. in total, 60 participants will take part in the study.

a double-blinded, randomized, placebo-controlled pilot study was designed to assess the effect of ellagitannins pomegranate supplements (eps) in metabolic health of participants. participants will be recruited at the family health unit usf são martinho de alcabideche from the grouping of health centres aces cascais, and the study will be conducted according to universal bioethical principles. at least 60 individuals with pre-diabetes will be included in the study. after the fulfilment of the inclusion criteria, they will be randomly assigned to the intervention group (ig) and the placebo group (pg). equal distribution of gender, age and bmi will be ensured between the groups.

Eligibility criteria:
inclusion criteria: * individuals without diabetes * both sexes * aged between 18 and 65 * body mass index (bmi) less than 29.9 kg/m2 * fasting plasma glucose levels below 126 mg/dl * haemoglobin a1c levels between 5.7 - 6.5% exclusion criteria: * not agreeing to take part in the study * bmi\>30 kg/m2 * being diagnosed with diabetes * having any type of cognitive disorder * using anti-diabetic medication * alcohol or drug abuse * pomegranate allergy * regular use of food supplements * difficulty swallowing tablets * being on, or planning to be on during the study period, a different diet than usual * pregnancy, planning to become pregnant during the study, breastfeeding 1 year before or during the study * oncological, cardiac, hepatic, renal, thyroid or other endocrine diseases * medical or social conditions that may affect adherence * participating in another study at the same time.

Keywords: prediabetes food supplement beta-cell function iapp urolithins
messaging strategies to reduce breast cancer over-screening in older women

Conditions: Breast Cancer Screening

Summary: this is an online survey experiment with data collection over 2 time points two weeks apart. this is aim 2 of a three-aim r01 project; overall project goal is to better understand how messages from different sources interact to affect older women's breast cancer screening decisions. in this current project, the investigators propose to test the effect of combined exposure to a clinician message + a message from another source (i.e. family/friend or media) on older women's breast cancer screening beliefs, attitudes, and intentions.

in a two-wave national online survey experiment, the investigators will randomly assign 3,000 women 65 years or older without personal history of breast cancer to 6 groups, including two control groups and four experimental groups. the experimental groups will read a message at time 1 (t1) that may be from either family/friend or the media followed by a second message from a clinician one to two weeks later at time 2 (t2). the clinician message will be directed at reducing over-screening, mentioning the harms of over-screening and supporting screening cessation. the investigators will systematically vary the non-clinician message to be either consistent with the clinician message (also mentions harms of over-screening and supports screening cessation) or conflicting (mentions benefits of screening, supports continued screening and opposes screening cessation). the investigators include a no-exposure control group (group 1) where the participants read no message at either time point and will only be asked the assessment questions. the investigators also include a single exposure group that reads only the clinician message (group 2).

Eligibility criteria:
inclusion criteria: * part of an online survey panel called knowledgepanel * able to complete survey in english exclusion criteria: * personal history of breast cancer
single incision transvaginal mesh in treatment of posterior vaginal wall prolapse

Conditions: Female Genital Prolapse

Summary: definition: to find out complications, objective and subjective outcomes of patients with symptomatic posterior vaginal wall prolapse undergoing posterior mesh operation in nine finnish hospitals during september 2010 and august 2013. the study hypothesis is that complications are acceptable and both objective and subjective outcomes are satisfying.

the aim of this study is to investigate the safety and efficacy of elevate®posterior transvaginal mesh kit. secondly the investigators want to evaluate the effect of this surgical method on non-affected anterior vaginal compartment as well as patients' outcome. this prospective multicenter national study include patients (n=111) with symptomatic posterior vaginal wall with or without apical prolapse with stage ii or more. patients were recruited at four university hospitals and five central hospitals in finland between september 2010 and august 2013. the study protocol was approved by the ethics committees in participating hospitals and all attending patients gave written consent after oral and written counseling. baseline evaluation include standardized gynecological examination in supine position using the pop-q system. detailed information on patients' characteristics and medical history is gathered, focusing on especially gynecological issues. patients fill in pelvic floor distress inventory (pfdi-20) and pelvic organ prolapse/urinary incontinence sexual questionnaire (pisq-12). the operations are performed by qualified surgeons (n=9) familiar with transvaginal mesh surgery. intraoperative data is collected and immediate postoperative problems are registered. the first follow-up visit take place at three months postoperatively. gynecological examination with pop-q measurements are performed and complications documented. as preoperatively, pfdi-20 and pisq-12 questionnaires are filled in by the patients. the second visit take place at one year postoperatively. gynecological examination with pop-q measurements are performed and possible late complications documented. pfdi-20 and pisq-12 questionnaires are filled in again by the patients.

Eligibility criteria:
inclusion criteria: * patients with symptomatic posterior vaginal wall with or without apical prolapse with stage ii or more exclusion criteria: * concomitant surgery, immunosuppressive treatment of any kind, previous or forthcoming bowel operation with low anastomosis creation and previous vaginal radiation therapy

Keywords: female prolapse surgery with transvaginal mesh subjective outcome
effectiveness of cognitive behavioral intervention in patients with symptoms somatization in primary care

Conditions: Quality of Life

Summary: the purpose of this study is to evaluate the efectiveness of a behavioral cognitive grupal intervention (bci) in patients with somatization symptoms which has an effect on the perceived quality of life front conventional intervention.

aim: to determine whether a cognitive-behavioral group intervention in patients with unexplicated somatic symptoms, that have come to the primary care medical in madrid, is more effective than normal practice in terms of improving life quality at one year. method: design:cluster randomized trial. setting: study in health centers primary care of area of madrid health service. unit of randomization are centres.analysis unit: patients between 18 and 65 years old. intervention: the cognitive behavioral grupal terapy in the internention group and the usual intervention in the control group. sample size adjusted for design effect=242 (121 in each arm). main response variable: preceived quality of life (sf-12). data analysis:comparison of the proportion of patients that improve in 4 or more points in the area of mental healthcare from the sf-12 in both groups,at 6 months and 1 year after patient inclusion.

Eligibility criteria:
inclusion criteria: * attending patients with 2 or more medically unexplained somatic symptoms during the last 6 months. * having came to medical examination on primary care at least 10 times during the last year. * be able to follow the trial´s demands, not have plans for moving another place and understand the spanish language. * patients who consent to take part. exclusion criteria: * diagnostics on serious mental disorder. * suicidal intentions at the moment of getting involved in the study. * diagnostics on addiction to toxic substances. * diagnostics on well-known body illness responsible for the symptoms. * previous psychotherapy during the previous year.

Keywords: primary health care somatization symptoms cognitive behavioral therapy nursing intervention